DaVita (DVA)
Healthcare · Medical - Care Facilities
4 members of Congress have disclosed 11 trades in DaVita (DVA) since 2018: 4 buys and 7 sales. The most recent was disclosed on Aug 5, 2026. 1 trade was made by members of a committee that oversees DaVita's industry.
- Trades disclosed
- 11
- Members trading
- 4
- Buys / sells
- 4 / 7
- Reported value
- $11K–$165K
Keep following the company.
Subscribers get new congressional filings and notable insider purchases for companies they follow. Coverage varies by company.
What else is happening at DVA
All research →Company filings and public records connected to this stock, ordered by when they became public or were first observed.
DVA: third_quarter 2026 lobbying report
A lobbying activity report was filed. Income and expenses are separate reporting measures and must not be added together.
Public: Oct 21, 2026, 2:25 PM EDTOriginal source ↗DVA: third_quarter 2026 lobbying report
Healthcare reimbursement policies; and issues relating to ESRD policies. Issues related to the budget and appropriations process. Issues relating to ESRD policies and reimbursement. Issues related to the Medicare Secondary Payer Act. S.1173: Restore Protections for Dialysis Patients Act H.R.2199 - Restore Protections for Dialysis Patients Act
Public: Oct 20, 2026, 10:45 PM EDTOriginal source ↗DVA: third_quarter 2026 lobbying report
Building support among disability and minority organizations in support of H.R. 6860 and S.1173. companion.
Public: Oct 20, 2026, 3:24 PM EDTOriginal source ↗DVA: third_quarter 2026 lobbying report
Issues related to Medicare ESRD payments and policy, including Medicare Advantage. Medicare reimbursement and Medicare Secondary Payer policies, including H.R. 2199 and S.1173.
Public: Oct 20, 2026, 3:07 PM EDTOriginal source ↗DVA: third_quarter 2026 lobbying report
H.R. 2199/S. 1173 - Restore Protections for Dialysis Patients Act - Issues related to Medicare Secondary Payer policies related to people with ESRD. Issues related to innovation-centered kidney care choices model. Issues related to hospice and dialysis.
Public: Oct 20, 2026, 12:30 PM EDTOriginal source ↗
Committee overlaps
Trades by members of a committee that oversees DaVita's industry. An overlap is a fact about the trade, not evidence of wrongdoing.
Who traded DVA
- Sen. Jerry Moran (R-KS)2 buys · 3 sales23Jan 17, 2024
- Rep. Julie Johnson (D-TX-32)1 buy · 2 sales12Aug 5, 2026
- Sen. Tommy Tuberville (R-AL)0 buys · 2 sales02Jan 12, 2024
- Sen. Alan Armstrong (R-OK)1 buy · 0 sales10Jul 21, 2026
All trades
- Aug 5, 2026$1K–$15K
Rep. Julie Johnson (D-TX-32)
$1K–$15K · Traded Sep 23, 2025 · disclosed Aug 5, 2026 · Joint · filed 316 days later
- Aug 5, 2026$1K–$15K
Rep. Julie Johnson (D-TX-32)
$1K–$15K · Traded Sep 23, 2025 · disclosed Aug 5, 2026 · Joint · filed 316 days later
- Jul 21, 2026$1K–$15K
Sen. Alan Armstrong (R-OK)
$1K–$15K · Traded Mar 27, 2026 · disclosed Jul 21, 2026 · filed 116 days later
Committee overlap: HELP - Oct 7, 2025$1K–$15K
Rep. Julie Johnson (D-TX-32)
$1K–$15K · Traded Sep 25, 2025 · disclosed Oct 7, 2025 · Joint
- Jan 17, 2024$1K–$15K
Sen. Jerry Moran (R-KS)
$1K–$15K · Traded Dec 14, 2023 · disclosed Jan 17, 2024
- Jan 17, 2024$1K–$15K
Sen. Jerry Moran (R-KS)
$1K–$15K · Traded Dec 14, 2023 · disclosed Jan 17, 2024 · Spouse
- Jan 12, 2024$1K–$15K
Sen. Tommy Tuberville (R-AL)
$1K–$15K · Traded Dec 12, 2023 · disclosed Jan 12, 2024 · Joint
- Jul 14, 2023$1K–$15K
Sen. Tommy Tuberville (R-AL)
$1K–$15K · Traded Jun 12, 2023 · disclosed Jul 14, 2023 · Joint
- Jan 21, 2022$1K–$15K
Sen. Jerry Moran (R-KS)
$1K–$15K · Traded Dec 21, 2021 · disclosed Jan 21, 2022
- May 15, 2019$1K–$15K
Sen. Jerry Moran (R-KS)
$1K–$15K · Traded Dec 6, 2018 · disclosed May 15, 2019 · filed 160 days later
- May 15, 2019$1K–$15K
Sen. Jerry Moran (R-KS)
$1K–$15K · Traded Dec 6, 2018 · disclosed May 15, 2019 · Spouse · filed 160 days later
From periodic transaction reports filed under the STOCK Act. Amounts are the ranges members report, and trades can be disclosed up to 45 days after they happen. Nothing here is investment advice.